ANIP has been the topic of a number of other reports. ValuEngine raised Xylem from a “hold” rating to a “buy” rating in a report on Friday, June 21st. Canaccord Genuity downgraded Magellan Aerospace from a “buy” rating to a “hold” rating and reduced their price target for the company from C$21.00 to C$20.00 in a research note on Monday, May 13th. Zacks Investment Research downgraded ExlService from a “hold” rating to a “sell” rating in a research note on Wednesday. Raymond James restated a “buy” rating on shares of Canadian Natural Resources in a research note on Friday, May 10th. Finally, TheStreet upgraded TerraForm Power from a “c” rating to a “b-” rating in a research note on Tuesday, March 19th. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $84.50.
ANIP stock opened at $81.36 on Thursday. The company has a debt-to-equity ratio of 0.33, a current ratio of 0.92 and a quick ratio of 0.67. The firm has a market cap of $962.23 million, a price-to-earnings ratio of 17.07 and a beta of 2.25. ANI Pharmaceuticals has a 1-year low of $36.92 and a 1-year high of $84.10. The business’s 50 day simple moving average is $75.21.
In other news, insider Arthur Przybyl sold 30,000 shares of the company’s stock in a transaction on Wednesday, May 15th. The stock was sold at an average price of $70.07, for a total transaction of $2,102,100.00. Following the completion of the sale, the insider now directly owns 222,994 shares in the company, valued at approximately $15,625,189.58. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director David Nash bought 1,445 shares of the business’s stock in a transaction dated Friday, May 24th. The shares were bought at an average price of $68.76 per share, with a total value of $99,358.20. Following the completion of the transaction, the director now owns 5,236 shares in the company, valued at approximately $360,027.36. The disclosure for this purchase can be found here. Over the last quarter, insiders have sold 50,911 shares of company stock valued at $3,585,114. Corporate insiders own 24.70% of the company’s stock.
Several large investors have recently added to or reduced their stakes in the company. WINTON GROUP Ltd boosted its position in shares of ANI Pharmaceuticals by 80.5% during the 2nd quarter. WINTON GROUP Ltd now owns 7,868 shares of the specialty pharmaceutical company’s stock valued at $647,000 after purchasing an additional 3,509 shares in the last quarter. First Trust Advisors LP boosted its holdings in ANI Pharmaceuticals by 1.2% in the first quarter. First Trust Advisors LP now owns 15,122 shares of the specialty pharmaceutical company’s stock worth $1,067,000 after acquiring an additional 179 shares in the last quarter. Marshall Wace LLP bought a new position in ANI Pharmaceuticals in the first quarter worth approximately $797,000. Phocas Financial Corp. boosted its holdings in ANI Pharmaceuticals by 8.9% in the first quarter. Phocas Financial Corp. now owns 140,977 shares of the specialty pharmaceutical company’s stock worth $9,945,000 after acquiring an additional 11,501 shares in the last quarter. Finally, Campbell & CO Investment Adviser LLC bought a new position in ANI Pharmaceuticals in the first quarter worth approximately $626,000. Hedge funds and other institutional investors own 63.92% of the company’s stock.
ANI Pharmaceuticals Company Profile
ANI Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncolytics (anti-cancers), hormones and steroids, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract manufacturing for other pharmaceutical companies.
Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.